Article Text

Download PDFPDF
Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
  1. Bengt Sorbe, MD, PhD*,
  2. Marianne Graflund, MD, PhD*,
  3. György Horvath, MD, PhD,
  4. Marie Swahn, MD,
  5. Karin Boman, MD, PhD,
  6. René Bangshöj, MD§,
  7. Margareta Lood, MD§ and
  8. Henric Malmström, MD, PhD
  1. * Department of Gynecological Oncology, University Hospital, Örebro;
  2. Department of Gynecological Oncology, Sahlgrenska University Hospital, Gothenburg;
  3. Department of Gynecological Oncology, University Hospital, Umeå;
  4. § Department of Gynecology and Obstetrics, Central Hospital, Karlstad; and
  5. Department of Oncology, University Hospital, Linköping, Sweden.
  1. Address correspondence and reprint requests to Bengt Sorbe, MD, PhD, Department of Gynecological Oncology, University Hospital, SE-701 85 Örebro, Sweden. E-mail: bengt.sorbe{at}


Objectives The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of patients with advanced-stage ovarian carcinoma treated with a first-line weekly docetaxel and 3 weekly carboplatin regimen.

Methods All eligible patients were treated with intravenous docetaxel (30 mg/m2) on days 1, 8, and 15, and carboplatin (area under the curve, 5) on day 1; every 21 days for at least 6 cycles.

Results One hundred six patients received at least one cycle of primary chemotherapy (median, 6.0; range, 1–9), and they were evaluable for toxicity assessment. Eighty-five patients had evaluable (measurable) disease and received at least 3 courses of chemotherapy and were evaluable for clinical response rate. The overall response rate was 78.8% (95% confidence interval, 70.1%–87.5%), and the biochemical response 92.8% (95% confidence interval, 87.2%–98.4%). The median progression-free survival was 12.0 months and the median overall survival was 35.3 months. Thirty-six patients (34.0%) experienced grades 3 and 4 neutropenia, which resulted in the removal of 3 patients. Six patients (5.7%) experienced grades 3 or 4 thrombocytopenia. No patients experienced grade 3 to grade 4 sensory neuropathy. Epiphora, nail changes, and fatigue were frequently recorded nonhematologic adverse effects.

Conclusions The tolerable hematologic toxicity (no need for colony-stimulating factors) and the low rate of neurotoxicity (only grades 1–2) and response rates in line with the standard 3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma after suboptimal cytoreductive surgery make this regimen an interesting alternative in selected patients.

  • Ovarian cancer
  • Docetaxel
  • Carboplatin
  • Weekly administration

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors received financial support from Sanofi-Aventis AB, Stockholm, Sweden.

  • The authors declare that there are no conflicts of interest.